G Protein–Coupled Receptor 30 Mediates the Anticancer Effects Induced by Eicosapentaenoic Acid in Ovarian Cancer Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: While numerous epidemiological studies have indicated that omega-3 polyunsaturated fatty acids have anticancer properties in various cancers, the effects and mechanisms of eicosapentaenoic acid (EPA) in ovarian cancer cell growth are poorly understood. Materials and Methods: ES2 ovarian clear cell carcinoma cells and SKOV3 adenocarcinoma cells were treated with palmitic acid or EPA, followed by flow cytometry and cell counting to measure apoptosis and proliferation, respectively. A modified protein lipid overlay assay was used to further verify whether EPA was a ligand of G protein–coupled receptor 30 (GPR30) in ES2 cells. The levels of apoptosis-related genes, phosphorylated AKT, and phosphorylated ERK1/2 were detected to explore the underlying mechanism. Finally, inhibitory effect of EPA on tumor growth via GPR30 was determined in vitro and in vivo. Results: EPA suppressed ES2 ovarian clear cell carcinoma cells growth via GPR30, a novel EPA receptor, by inducing apoptosis. As a ligand of GPR30, EPA activated the GPR30-cAMP– protein kinase A signaling pathway. When GPR30 was suppressed by siRNA or its inhibitor G15, the antiproliferative action of EPA was impaired. Furthermore, EPA inhibited tumor growth by blocking the activation of AKT and ERK. In the mouse xenograft model, EPA decreased tumor volume and weight through GPR30 by blocking tumor cell proliferation. Conclusion: These results confirm that EPA is a tumor suppressor in human ovarian clear cell carcinoma cells and functions through a novel fatty acid receptor, GPR30, indicating a mechanistic linkage between omega-3 fatty acids and cancers.
Abstract
Purpose: While numerous epidemiological studies have indicated that omega-3 polyunsaturated fatty acids have anticancer properties in various cancers, the effects and mechanisms of eicosapentaenoic acid (EPA) in ovarian cancer cell growth are poorly understood. Materials and Methods: ES2 ovarian clear cell carcinoma cells and SKOV3 adenocarcinoma cells were treated with palmitic acid or EPA, followed by flow cytometry and cell counting to measure apoptosis and proliferation, respectively. A modified protein lipid overlay assay was used to further verify whether EPA was a ligand of G protein–coupled receptor 30 (GPR30) in ES2 cells. The levels of apoptosis-related genes, phosphorylated AKT, and phosphorylated ERK1/2 were detected to explore the underlying mechanism. Finally, inhibitory effect of EPA on tumor growth via GPR30 was determined in vitro and in vivo. Results: EPA suppressed ES2 ovarian clear cell carcinoma cells growth via GPR30, a novel EPA receptor, by inducing apoptosis. As a ligand of GPR30, EPA activated the GPR30-cAMP– protein kinase A signaling pathway. When GPR30 was suppressed by siRNA or its inhibitor G15, the antiproliferative action of EPA was impaired. Furthermore, EPA inhibited tumor growth by blocking the activation of AKT and ERK. In the mouse xenograft model, EPA decreased tumor volume and weight through GPR30 by blocking tumor cell proliferation. Conclusion: These results confirm that EPA is a tumor suppressor in human ovarian clear cell carcinoma cells and functions through a novel fatty acid receptor, GPR30, indicating a mechanistic linkage between omega-3 fatty acids and cancers.
참고문헌 (30)
- Sapienza C, "Diet, nutrition, and cancer epigenetics", Annu Rev Nutr, 36, pp.665~681 (2016)
- Rose DP, "Omega-3 fatty acids as cancer chemopreventive agents", Pharmacol Ther, 83, pp.217~244 (1999)
- Velentzis LS, "Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study", Breast Cancer Res Treat, 128, pp.473~482 (2011)
- Jemal A, "Cancer statistics, 2010", CA Cancer J Clin, 60, pp.277~300 (2010)
- Brinton EA, "Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid(EPA)", Lipids Health Dis, 16, pp.23~ (2017)
- Santos CR, "Lipid metabolism in cancer", FEBS J, 279, pp.2610~2623 (2012)
- Maggiolini M, "The unfolding stories of GPR30, a new membrane-bound estrogen receptor", J Endocrinol, 204, pp.105~114 (2010)
- Heublein S, "The G-protein-coupled estrogen receptor(GPER", GPR30)in ovarian granulosa cell tumors, 2014, pp.15, 15161~15172
- I in mesenteric microvessels of female rat, "J Pharmacol Exp Ther", 2015, 291~304
- Jin J, "RhoA downstream of G(q)and G(12", 13)pathways regulates protease-activated receptor-mediated dense granule release in platelets, 2009, pp.77, 835~844
- Taniguchi M, "YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666", J Antibiot (Tokyo), 56, pp.358~363 (2003)
- Wang C, "The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner", Am J Transl Res, 4, pp.390~402 (2012)
- Bai LY, "G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squamous carcinoma cells", Chem Biol Interact, 206, pp.375~384 (2013)
- Pal D, "Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance", Nat Med, 18, pp.1279~1285 (2012)
- Hu L, "Association of Vimentin overexpression and hepatocellular carcinoma metastasis", Oncogene, 23, pp.298~302 (2004)
- Sugiyama T, "Clinical characteristics of clear cell carcinoma of the ovary : a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy", Cancer, 88, pp.2584~2589 (2000)
- Landrum LM, "Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy : a Gynecologic Oncology Group study", Gynecol Oncol, 130, pp.12~18 (2013)
- Kwan HY, "Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway : role of palmitic acid", J Biol Chem, 289, pp.30525~30537 (2014)
- Sun H, "Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway", Carcinogenesis, 32, pp.1518~1524 (2011)
- Kotarsky K, "A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs", Biochem Biophys Res Commun, 301, pp.406~410 (2003)
- Gu Z, "Mechanisms of omega-3polyunsaturated fatty acids in prostate cancer prevention", Biomed Res Int, 2013, pp.824563~ (2013)
- Dorsam RT, "G-protein-coupled receptors and cancer", Nat Rev Cancer, 7, pp.79~94 (2007)
- Prossnitz ER, "The ins and outs of GPR30 : a transmembrane estrogen receptor", J Steroid Biochem Mol Biol, 109, pp.350~353 (2008)
- Shu YJ, "SPOCK1as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K", AKT pathway, 2015, pp.14, 12~
- Brazil DP, "Advances in protein kinase B signalling : AKTion on multiple fronts", Trends Biochem Sci, 29, pp.233~242 (2004)
- Castoria G, "Integrating signals between cAMP and MAPK pathways in breast cancer", Front Biosci, 13, pp.1318~1327 (2008)
- Nieman KM, "Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth", Nat Med, 17, pp.1498~1503 (2011)
- Fukui M, "EPA, an omega-3 fatty acid, induces apoptosis in human pancreatic cancer cells : role of ROS accumulation, caspase-8 activation, and autophagy induction", J Cell Biochem, 114, pp.192~203 (2013)
- Sabharwal SS, "Mitochondrial ROS in cancer:initiators, amplifiers or an Achilles' heel?", Nat Rev Cancer, 14, pp.709~721 (2014)
- Gajate C, "Lipid raft connection between extrinsic and intrinsic apoptotic pathways", Biochem Biophys Res Commun, 380, pp.780~784 (2009)